INNOVENT BIO (01801) has announced a strategic collaboration with Eli Lilly and Company to jointly advance the global research and development of innovative drugs in the fields of oncology and immunology. This agreement marks the seventh collaboration between the two parties, further deepening their long-term and productive partnership as they work together to bring novel therapeutics to patients worldwide. The unique structure of this cooperation establishes a new collaborative model for the company, accelerating the globalization of its innovative R&D pipeline. Under the agreement, both companies will leverage their complementary strengths to expedite the global development of innovative medicines. INNOVENT BIO will lead R&D activities for relevant programs from drug discovery through proof-of-concept clinical trials in China, utilizing its established antibody technology platform and efficient clinical development capabilities. Eli Lilly has obtained exclusive global development and commercialization rights for the programs outside Greater China, while INNOVENT BIO retains full rights within Greater China. As part of the agreement, INNOVENT BIO will receive an upfront payment of $350 million. Upon achieving certain future milestones, the company is also eligible to receive up to approximately $8.5 billion in additional payments tied to development, regulatory, and commercial milestones. Furthermore, INNOVENT BIO is entitled to receive tiered royalties on net sales of each product outside Greater China. This collaboration breaks through the limitations of traditional licensing models by creating an integrated, end-to-end innovation ecosystem. It deeply combines INNOVENT BIO's agile and efficient drug discovery and early-stage development capabilities with Eli Lilly's extensive global footprint, establishing a highly effective synergistic partnership. This cooperation fully demonstrates INNOVENT BIO's core R&D strength and will assist the company and its partner in accelerating the translation of scientific discoveries into globally impactful medical solutions, ultimately delivering world-class innovative drugs to patients around the world.